In ex vivo studies of MM patient samples, we evaluated MATCH efficacy by measuring the frequency of MM cells (CD45−/CD19−/CD138+/CD38+) within the viable cell population for each patient.[30] Patient information on cytogenetics and previous treatment regimens is shown in Table 1. This evidence concerns the gene SDC1 and Miyoshi myopathy.